Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: J Stone who wrote (29367)	11/9/1999 12:13:00 AM
From: bob zagorin	Read Replies (1) \| Respond to of 32384

LGND doesn't act like most stocks as it will decline will showing accumulation or vice versa. IAE, BOP (demand) is definitely improving although Moneystream is still pretty low. We're still below where the stock was early in the year so there are still some tax sellers out here. OTHO, LGND is usually strong from the fall to early spring. Bottom line, no clear answers but picture is improving.

To: J Stone who wrote (29367)	11/22/1999 8:52:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

FDA Advisory Meeting on Targretin: fda.gov Oncologic Drugs Advisory Committee Meeting. Date and Time: December 13, 1999, 9 a.m. and December 14, 1999, 8 a.m. Location: Holiday Inn, Versailles Ballroom, 8120 Wisconsin Ave., Bethesda, MD. Contact: Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD-21), 301-827-7001. On December 13, 1999, the committee will discuss: (1) New drug application (NDA) 21-055, Targretin (bexarotene) Capsules, 75 milligrams, Ligand Pharmaceuticals, Inc., indicated for the treatment of patients with all clinical stages (IA-IVB) of cutaneous T-cell lymphoma (CTCL) in the following categories: Patients with early stage CTCL who have not tolerated other therapies, patients with refractory or persistent early stage CTCL, and patients with refractory advanced stage CTCL; and (2) NDA 20-449/S-011, Taxotere (docetaxel) for Injection Concentrate, Rhone-Poulenc Rorer Pharmaceuticals, Inc., indicated for the treatment of patients with locally advanced or metastatic Non-small Cell Lung Cancer after failure of prior chemotherapy. On December 14, 1999, the committee will discuss: (1) The design and analysis of active control clinical trials; and (2) NDA 21-156, CelebrexTM (celecoxib), G. D. Searle & Co., indicated for the regression and prevention of adenomatous polyps, which may lead to the development of colorectal cancer in patients with familial adenomatous polyposis.